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2012 were analyzed for their ASMR ratings. Analysis were conducted to identify
new trends and compare them for products based on their indications, compara-
tors and launch timing. RESULTS: Analysis of 2011-2012 assessments by TC shows
that majority of products (73%) received an ASMR rating of IV (minor improve-
ment). Approximately 27% of the products received an ASMR rating of III and V. A
new trend in TC’s assessment is the assignment of two ASMR ratings for one
product for different subgroups or patient line of treatment. During last one year 3
out of 11 products received two ASMR ratings. None of the products received ASMR
ratings of I and II. The products that received ASMR rating of V (no improvement)
were indicated for cardiovascular, epilepsy and bone metastases. All assessments
included analysis of intervention’s data versus one or more comparators.
CONCLUSIONS: France TC’s assessments trends show need for robust comparative
effectiveness data to obtain better ASMR ratings, which affects both pricing and
market access of new products. Future products would need subgroup analysis to
obtain high ASMR ratings for all patient populations.
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OBJECTIVES: Safe endoscope reprocessing requires meticulous adherence to
guidelines. Human error is a principal cause of deficient reprocessing. Approaches
vary from fully manual processes, to semi-automatic reprocessors, or fully auto-
mated cleaner and reprocessors. We assessed key issues in endoscope reprocess-
ing related to guideline adherence, health and resource outcomes and staff burden.
METHODS: PubMed was searched from January 1, 2007 to March 7, 2012. Search
terms: ((Endoscope OR endoscopy) AND (Reprocessing OR Cleaning OR Disinfection
OR Biofilms)). Abstracts were screened by 2 independent reviewers and included
according to research areas: 1) adherence to endoscope reprocessing guidelines; 2)
endoscopy related adverse contamination outcomes and; and 3) adverse effects of
endoscope reprocessing on staff. Reference lists of key papers were searched.
RESULTS: Six studies assessed guideline adherence. Non-adherence levels varied
considerably with a trend for less developed health care systems to have poorer
adherence. For study question 2, 19 articles reported 7 infection outbreaks, 6 pseu-
do-outbreaks and 4 toxic reactions related to endoscope procedures. The majority
of events could have been prevented if standard reprocessing practices were fol-
lowed. Eight studies (1 each from Canada, Japan and US and 5 from Europe) con-
sidered the impact of device reprocessing on staff health, time, or the associated
costs. Two studies reported that manual reprocessing had a significant health
impact on staff including respiratory ailments and physical discomfort. One study
reported that in a single hospital reprocessing time was 6.2 hours longer per day
with manual vs. automated procedures; this had a resultant impact on costs.
CONCLUSIONS: Effective reprocessing is vital to ensure safe use of endoscopes.
Guideline adherence is variable, and poor standards can lead to adverse outcomes.
Manual reprocessing is associated with considerable health burdens for staff. Au-
tomated reprocessing could improve guideline adherence and reduce the burden
on staff, as well as reduce costs. Further studies in this area are warranted.
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ANALYSIS OF THE REIMBURSEMENT DECISIONS OF THE NATIONAL HEALTH
INSURANCE FUND OF HUNGARY (2007-2011)
Botlik O, Kalotai Z
Novartis Hungary, Budapest, Hungary
OBJECTIVES: Our goal was to analyze the Hungarian drug reimbursement deci-
sions - through the reimbursement of new molecular entities (NME) in the period of
2007-2011. METHODS: NME’s were collected from the official drug reimbursement
list published monthly on the website of the National Health Insurance Fund of
Hungary (NHIF). Drugs with hospital reimbursement were excluded from the anal-
ysis, as their reimbursement process differs. There are two ways to reimburse an
Rx NME in Hungary: Route A: NHIF is the final decision maker, there is no need for
legislation change. Route B: In case of e.g. new restricted indication or a new ATC4
level of a given NME, the final decison makers are, Ministry of Health & previously
Ministry of Finance, currently Ministry of Economy. In these latest cases a minis-
terial decree is published, containing the reimbursement list of NME’s. RESULTS:
Within the observed period 86 new molecules gained reimbursement from the
Drug Budget. The most NME’s gained reimbursement in 2008 (23 NME’s). A total of
33% of the products belong to two ATC categories: A and L, and most of NME’s (40%)
are fully reimbursed. 34 % of the products needed Route B to gain reimbursement.
More than half of these products (16 molecules) gained reimbursement in 2008,
however no such decision was made in 2009 and only 3 molecules have been
reimbursed in 2010 and 2011, respectively! CONCLUSIONS: The number of reim-
bursement decisions made through Route A didn’t change in this 5-year period.
However the number of Route B reimbursement decision dropped significantly
from 2008, resulting a significant market access delays for the Hungarian patients.
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OBJECTIVES: To suggest a new classification of different pharmaceutical payment
methods and to analyze the implementation of those methods in different health
care settings of IQ Partners’ Countries. This division will facilitate the comparative
analysis of the impact of different payment methods on health care costs, effi-
ciency, quality and equity. METHODS: Data on pharmaceutical payment methods
were obtained through a review of the available literature. The search included
relevant economic and medical databases, journals and books, conference mate-
rials and other projects. Different examples of payment methods were extracted
from publications (95 positions) and classified. The implementation of those meth-
ods in different countries was also described. RESULTS: The practical classification
of pharmaceutical payment methods was based on two main categories: tradi-
tional (well established and widely used) and innovative (implemented in recent
years, depending on the country). A sub-classification was also outlined, related to
the regulatory mechanisms of the methods in question: market driven, adminis-
trative regulations and market mechanisms with administrative settings (mixed).
The traditional payment methods and schemes include: “free” prices, fixed prices,
flexible prices, fixed budget, reference pricing, margins, rebate agreements, bonus
agreements and patient’s co-payment. The innovative payment methods include
price volume agreements, cross-product agreements, risk-sharing, value-based
pricing, framework agreements, cost-plus pricing, patient access schemes, portfo-
lio deals, one price per patient, disease management. The second group was sub-
sequently introduced in selected countries, including UK and US with a trend to be
used in others countries (e.g. Poland). CONCLUSIONS: Innovative payment meth-
ods allow risk-sharing both related to costs and outcomes creating an additional
platform for a dialogue between authorities and producers.
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OBJECTIVES: Point-of-care (POC) testing, also called near-patient, bedside, alter-
nate-site or decentralized testing, includes all in vitro testing where conduct and
analysis occurs outside the laboratory setting (e.g., physician office, at home), and
within a short time period while the patient waits. Development of POC diagnostic
tests (POCTs) has been on the rise in recent years and promises to reduce health
care costs by reducing utilization of costly centralized laboratory-based testing, the
need for follow-up office visits by patients to review laboratory test results, and/or
sample shipment and storage. Despite the potential of POC testing, health systems
and payers have been slow to adopt and reimburse such tests. To examine key
issues influencing POCT reimbursement and market access, global health technol-
ogy assessments (HTAs) were evaluated to identify stakeholder concerns contrib-
uting to the slow penetration of POCTs. METHODS: Published global POCT HTA
recommendations were identified and reviewed to provide insights into criteria
scrutinized and concerns registered by HTA agencies. RESULTS: POCT HTAs iden-
tified included those for cardiovascular, endocrine, oncologic, pulmonary/allergic,
and infectious diseases, and those informing therapeutic or illicit drugs. In assess-
ing POCTs, agencies scrutinized criteria generally fitting into four categories of
evidence including Testing Logistics, Clinical Validity/Utility, Economic Value/
Cost, and Ethical Concerns. For Testing Logistics: agencies scrutinized test turn-
around time, platform accessibility and current penetration, required sample size,
specimen collection and transport, and result/quality tracking; Clinical Validity/
Utility: test performance (e.g., sensitivity, specificity, false positives/negatives) and
agreement with/efficacy relative to lab-based tests, and impact on provider deci-
sion-making/patient outcomes; Economic Value/Cost: cost-offsets, cost-effective-
ness, and cost-minimization; Ethical Concerns: implications of erroneous results
and privacy issues. CONCLUSIONS: POC testing approaches hold potential to re-
duce health care costs while maintaining or improving patient outcomes. Evidence
required to support POCT HTA should be considered during development of new
POCTs to increase the likelihood of achieving reimbursement and market access.
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OBJECTIVES: Biosimilars are off-patent biologicals that shall provide cost savings
and greater accessibility to biopharmaceuticals. Within the next five years, several
top-selling biologics like Herceptin, Enbrel, Humalog, are due to loose patent pro-
tection. This opens business opportunities, but little is known about the biosimilar
market. The main biosimilar product classes are biosimilars of Epoetine (EPO),
Granulocyte-Colony Stimulating Factor (G-CSF) and Growth Hormoes (GH). Market
penetration levels for these biosimilars differ substantially across Germany,
France, UK, Italy and Spain (EU5). Literature does not provide an stringent expla-
nation for these differences.We attempt to fill this gap by explaining the diverse
levels of biosimilar uptake. METHODS: We model the diffusion process of biosimi-
lars in pharmaceutical markets with a Bass diffusion model. Model parameters are
estimated from IMS Health sales data on three Biosimilar classes in the EU5 coun-
tries. The estimated model parameters differ across countries and products. To
explain these differences, we conduct several expert interviews.The theoretical
lense guiding the interviews is Rogers theory of innovations and how properties of
an innovation influence diffusion. RESULTS: We find that Germany and France
account for approximately half the biosimilars market by value and a 34% and 17%
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market share across Europe. G-CSFs have achieved the highest market penetration
levels by value and GH the lowest across Europe. We identify four main drivers of
market penetration differences. Price has the highest impact along with the re-
sponse rate to the therapy. The efficacy of biosimilars in clinical trials as well as the
economic mind-set of prescribers (office-based vs. hospital-based) also drive bio-
similar market uptake. CONCLUSIONS: The study concludes with policy implica-
tions to regulate the uptake of biosimilars given different market conditions.
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OBJECTIVES: The recent AMNOG health care reforms in Germany provide a unique
view of a changing pricing system in Europe. With other European markets such as
the UK planning similar reforms, we aimed to review the impact of AMNOG on drug
pricing in Germany and distil lessons for other markets facing similar reforms.
METHODS: Secondary research was conducted to review IQWiG’s benefit assess-
ment activity since the AMNOG reforms. The outcomes of these benefit assess-
ments were assessed alongside rationale for decisions and pricing outcomes.
RESULTS: At the time of writing, 24 products have been subject to benefit assess-
ments by IQWiG. Of these, 12 were considered to show some level of added benefit
relative to the comparator, with the remainder showing no benefit. Selection of
inappropriate comparators was commonly cited by IQWiG as a reason that no
additional benefit was demonstrated. Under AMNOG, products displaying no
added benefit will be subject to automatic reference pricing, subjecting these prod-
ucts to generic pricing levels. As a result, there have been a number of high profile
instances of manufacturers withdrawing products from the German market as a
result of negative benefit assessment – most notably GSK with Trobalt and Pfizer
with Xiapex. In instances where additional benefit is shown, Brilique is currently
the only product has progressed through price negotiations with the GKV, resulting
in a modest price premium. CONCLUSIONS: The AMNOG reforms provide an ex-
cellent live example of a national level shift towards a “value based” pricing sys-
tem. The benefit assessments and consequent price levels may provide an indica-
tor of pricing that may be achieved following the implementation of value based
pricing in the UK. However, policy makers in the UK should be conscious of the
potential negative implications of these reforms in the way of product withdraw-
als.
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OBJECTIVES: A number of jurisdictions have adopted special funding arrange-
ments to provide extra payments to hospitals using certain technological innova-
tions to encourage use where existing financing may be absent or insufficient. The
objective of this research was to explore the use of these arrangements for medical
technologies in the English NHS. METHODS: A structured on-line survey instru-
ment was developed to gain insights into the use of special payments. An invitation
to participate with a link to the on-line survey was disseminated to NHS hospital
Finance Managers. A total of 25 surveys were returned and analysed. RESULTS:The
majority (75%) of responding hospitals have sought support from Commissioners
to approve special payments. In 35% of cases, the payment was for medical devices,
followed by drugs (31%), diagnostics (19%), and other technologies (15%). Respon-
dents highlighted specific technologies where special payments have been nego-
tiated, including Transcatheter Heart Valves, Neuromodulation Implants, and Gas-
tric Bands, among others. In most cases, such arrangements were requested
because the technology was either excluded from the PbR system or the existing
HRG tariff was not sufficient to cover costs. In half of the examples, the technology
was fully or partially paid for. However, it was not uncommon for Commissioners
to request additional evidence before making a decision or reject special payment
applications altogether. A range of evidence (therapeutic benefit, reduced hospital
admissions/length of stay, costs/cost-effectiveness) is considered to determine
payment amounts. Once negotiated, payment arrangements are typically put in
place for 1-3 years. Overall, NHS managers had mixed perceptions of the effective-
ness of special payments and identified several challenges, such as a disinterest
and insufficient expertise amongst Commissioners to consider submitted evidence
and the length of time to agree payments. CONCLUSIONS:While special payments
provide some flexibility for encouraging the adoption of technological innovation,
a number of improvements are needed to effectively meet this aim.
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OBJECTIVES: Since 2008 the Czech legislation requires health economic analysis
(HEA) to be a part of all new drug reimbursement applications submitted to State
Institute for Drug Control (SUKL): without any specific guidelines, however. In order
to see the real-world impact of the legislation change, we investigated past (2008/
2009) innovative molecules’ dossiers in terms of quality of their HEAs according to
newly (2012) developed methodology of SUKL and also their impact on the respec-
tive decisions on coverage. METHODS: We selected all (22) applications for inno-
vative drugs limited to specialized centers. We then briefly described the HEAs in
terms of their perspective and type of analysis. The HEAs were further confronted
with a ‘HEA checklist’ based on the new SUKL methodology to identify common
drawbacks and faulty issues in past HEAs. Consequently the respective coverage
decisions were investigated. RESULTS: Of the innovative molecules’ 22 dossiers
investigated, only in 13 (59%) HEA was present. Two (15%) were cost-minimization
studies, the rest were cost-effectiveness analyses, of which three (23%) were cost-
utility. There was no apparent standardization in the analyses along with an obvi-
ous lack of transparency. Indeed, ‘proper description of input data and their
sources’ was the point in the HEA checklist to be most often marked as ‘unsatis-
factory’. Review of the consequent SUKL’s coverage decisions revealed that, irre-
spective of the HEA quality and even presence, all 22 (100%) applications were given
a positive coverage decision. CONCLUSIONS: The present pilot study showed that
in the first two years since introducing the obligation of health economic analyses
be part of coverage applications, the system was largely ineffective. This finding
stresses the necessity of introduction of a standardized methodology into the as-
sessment and appraisal processes. Moreover, our study identified the key problem-
atic areas to be specifically addressed by both the authors and assessors of future
analyses.
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HOW WILL HEALTH CARE REFORM IN RUSSIA AFFECT DRUG PRICING AND
REIMBURSEMENT?
Wild L, Forster L
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OBJECTIVES: In an effort to remedy a highly fragmented system of health care
financing, Russia has introduced a series of reforms targeted streamlining public
and private funding. We aimed to understand how the recent reforms have im-
pacted pricing and reimbursement and how this is expected to change in the
future.METHODS:We conducted in-depth secondary research through an analysis
of Russian health care policies including the new DLO reimbursement programme
and the Essential and Most Important Medicines List (EML). Research was also
conducted on the roles of private insurance companies and private out-of-pocket
expenses. Expectation of how these reforms will shape pricing and reimbursement
in the future was assessed through a qualitative survey of key payers. RESULTS:
Increases in the percentage of GPD spent on health care and the procurement of
additional funding have led to a boom in the size of the Russian pharmaceutical
market. However, although medicines on the EML are fully reimbursed, coverage
does not include drugs for most outpatients, resulting in significant out-of-pocket
spending. Private insurers have also failed to produce competition due to lack of
incentives and legislation has caused rises in drug pricing. Payers expect that eco-
nomic growth and increased government spending on health care will continue to
increase the commercial attractiveness of the Russian pharmaceutical market.
However, several competing factors may cause legislative barriers to entry and
create a more challenging pricing and reimbursement environment. These con-
cerns arise from a newly imposed price cap on EML medicines, the exclusion of
certain drugs from the EML, legislation encouraging domestic growth, and a lack of
transparency regarding reimbursement decisions. CONCLUSIONS: New drug pric-
ing regulations and funding will likely create advantages for domestic pharmaceu-
tical companies while potentially decreasing foreign presence by creating a
tougher pricing and reimbursement environment.
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INDICATIONS
Félix J1, Vandewalle B1, Silva MJ2, Almeida J1, Rabiais S1
1Exigo Consultores, Alhos Vedros, Setúbal, Portugal, 2Exigo Consultores, Alhos Vedros, Lisbon,
Portugal
OBJECTIVES: Accessibility (time to financing decision) to new medicines is a major
concern in Europe. Recently the European Commission has proposed to streamline
and reduce the duration of national decisions on pricing and reimbursement of
new medicines. The objective of this study was to evaluate the accessibility to
medicinal products with new molecules or new therapeutic indications (NMNTI) in
Portugal, since 2007 and characterize the determinants of the assessment process
by the Portuguese Ministry of Health. METHODS: Data on 119 NMNTI reimburse-
ment applications to the PMH between January 2007 and June 2011 was kindly
provided by submitting pharmaceutical companies. Time to financing decision
was assessed using the Turnbull non-parametric estimator and variability in time
to financing decision was explored using accelerated failure time regression mod-
els with Gaussian mixture distributions, both allowing for interval, left and right
censoring. The likelihood of public financing and its determinants was evaluated
through the estimation of logistic regression models. RESULTS: Median time from
submission to decision 331 days (95%CI: 292-398) was excessive relative to those in
the Law for the decision: 70 days (hospital) and 110 days (ambulatory). In hospital
medicines no decision was taken in less than 70 days. Only 10% of the decisions
from ambulatory drugs were taken within the timelines in the law. Of particular
concern was median decision times for orphan medicines (718 days), oncology
drugs (743 days) and new therapeutic indications of medicines already reimbursed
(890 days). From a vast number of variables studied, only in cardiovascular medi-
cines the likelihood of non-public financing was significant lower (p0.026).
CONCLUSIONS:Accessibility to new medicines or medicines with new therapeutic
indications in Portugal is compromised by an excessively long assessment process
by the Portuguese Ministry of Health. Of particular concern is accessibility to or-
phan and oncology drugs.
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